Cantor Fitzgerald Issues Negative Outlook for ARTV Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of Artiva Biotherapeutics in a research report issued on Tuesday, March 25th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($2.91) for the year, down from their prior estimate of ($2.72). Cantor Fitzgerald has a “Overweight” rating and a $20.00 price objective on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

Other equities research analysts have also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a report on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Trading Down 2.7 %

NASDAQ:ARTV opened at $3.54 on Thursday. The company’s 50-day moving average is $4.78 and its two-hundred day moving average is $9.29. Artiva Biotherapeutics has a 1-year low of $3.37 and a 1-year high of $17.31.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently bought and sold shares of ARTV. Deutsche Bank AG purchased a new stake in Artiva Biotherapeutics during the fourth quarter worth approximately $216,000. BNP Paribas Financial Markets grew its position in shares of Artiva Biotherapeutics by 262.1% in the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock valued at $100,000 after buying an additional 7,151 shares during the last quarter. Northern Trust Corp raised its stake in Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock worth $1,180,000 after acquiring an additional 4,335 shares in the last quarter. Barclays PLC lifted its position in Artiva Biotherapeutics by 23.2% in the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock valued at $244,000 after acquiring an additional 4,545 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Artiva Biotherapeutics by 64.0% in the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after acquiring an additional 3,361 shares in the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.